BCMA-Directed Bispecific Antibodies in Early Relapse Multiple Myeloma

EP. 1: Defining Early Relapse and Treatment Selection in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

EP. 2: Unmet Needs in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

EP. 3: Role of Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

EP. 4: Interpreting MajesTEC-3 Efficacy in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

EP. 5: Subgroup Insights in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 15th 2026

EP. 6: Safety Considerations for Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 15th 2026

EP. 7: Managing Toxicities of Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 22nd 2026

EP. 8: Mechanistic Rationale and Combination Strategies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 22nd 2026

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

EP. 9: Discussing Proper Utilization of BCMA Bispecifics in Early Relapse Multiple Myeloma

ByONCOLOGY Staff

April 24th 2026

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

EP. 10: Positioning Bispecific Therapy in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 29th 2026

EP. 11: Case-Based Sequencing Decisions in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 29th 2026

EP. 12: Sequencing CAR-T and Bispecifics in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 6th 2026

EP. 13: Risk Stratification and Shared Decision-Making in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 6th 2026

EP. 14: Managing Comorbid Patients in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 13th 2026

EP. 15: Key Takeaways for Early Relapse Multiple Myeloma Management

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 13th 2026

BCMA-Directed Bispecific Antibodies in Early Relapse Multiple Myeloma

EP. 1: Defining Early Relapse and Treatment Selection in Multiple Myeloma

EP. 2: Unmet Needs in Early Relapse Multiple Myeloma

EP. 3: Role of Bispecific Antibodies in Multiple Myeloma

EP. 4: Interpreting MajesTEC-3 Efficacy in Multiple Myeloma

EP. 5: Subgroup Insights in Early Relapse Multiple Myeloma

EP. 6: Safety Considerations for Bispecific Antibodies in Multiple Myeloma

EP. 7: Managing Toxicities of Bispecific Antibodies in Multiple Myeloma

EP. 8: Mechanistic Rationale and Combination Strategies in Multiple Myeloma

EP. 9: Discussing Proper Utilization of BCMA Bispecifics in Early Relapse Multiple Myeloma

EP. 10: Positioning Bispecific Therapy in Early Relapse Multiple Myeloma

EP. 11: Case-Based Sequencing Decisions in Early Relapse Multiple Myeloma

EP. 12: Sequencing CAR-T and Bispecifics in Early Relapse Multiple Myeloma

EP. 13: Risk Stratification and Shared Decision-Making in Early Relapse Multiple Myeloma

EP. 14: Managing Comorbid Patients in Early Relapse Multiple Myeloma

EP. 15: Key Takeaways for Early Relapse Multiple Myeloma Management

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?

Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care

TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer

Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC